Openness and transparency of clinical trials data as the key factor for protection of general public, healthcare professionals, the industry, and the government
Publication of clinical trials data is one of the key methods of assuring reliability of clinical trial conclusions. Publication of clinical data has been and is among the main topics in European and American regulatory authorities' agenda. Ultimately, European Union regulatory bodies have given public access to clinical trials reports, and open access to these data is upcoming in the United States in early 2017. Restricted access to clinical data put various barriers for medicinal products manufacturers and medicinal products consumer. Therefore, providing public access to clinical trials reports will increase activity in clinical development and will facilitate marketing authorization of medicinal products whose safety and efficacy have been demonstrated using scientifically sound methods.